Using the immune system to kill tumours
- Research Opportunity
- PhD, Honours, Master of Biomedical Science
- Biochemistry and Molecular Biology
- Bio21 Molecular Science and Biotechnology Institute
|Dr Justine Minternfirstname.lastname@example.org||83442976||Personal web page|
|Professor Jose Villadangosemail@example.com||Personal web page|
Immune checkpoint proteins include PD1, PD-L1 and PD-L2. These proteins are expressed by tumours and immune cells and prevent the develop of an effective anti-tumour immune response. Checkpoint protein inhibitors are being used in the clinic to enhance tumour immunotherapy. In this project, we aim to understand how the expression of checkpoint proteins is regulated. We will investigate when PD1, PD-L1 and PD-L2 molecules are expressed and the underlying molecular mechanisms that controls this response. We will examine expression of checkpoint proteins using a model of adoptive T cell immunotherapy for B cell lymphoma. In addition, we will undertake CRISPR/Cas9 genetic deletion to identify new molecules that are involved in the expression of PD1, PD-L1 and PD-L2 at the surface of immune cells and tumours.
Faculty Research Themes
School Research Themes
PhD, Honours, Master of Biomedical Science
Students who are interested in joining this project will need to consider their elegibility as well as other requirements before contacting the supervisor of this research
For further information about this research, please contact a supervisor.
Research Group / Unit / Centre
Research NodeBio21 Molecular Science and Biotechnology Institute
MDHS Research library
Explore by researcher, school, project or topic.